Solid Biosciences (SLDB) Stock Forecast & Price Target

Solid Biosciences is viewed favorably because SGT-003 appears differentiated in DMD through targeted muscle delivery, preserved nNOS function, consistent microdystrophin expression, and a cleaner safety profile with no drug-induced liver injury in 53 dosed patients. The company also benefits from a simpler steroid-only prophylactic regimen and a more constructive FDA backdrop, with 53 patients dosed, a randomized confirmatory trial already underway, and a late-4Q26 meeting that could support accelerated approval. Beyond DMD, SGT-212, SGT-501, and SGT-601 add optionality, while the market still leaves substantial untreated DMD prevalence and appears to underwrite only a fraction of the platform’s commercial potential.

Solid Biosciences is viewed negatively because its core gene-therapy platform faces unusually high clinical and regulatory risk, with questions around microdystrophin validity, unproven surrogate endpoints in Friedreich’s ataxia, and the possibility that safety events or a clinical hold could undermine the entire portfolio. The company’s programs remain early and execution-dependent, while competition in DMD and FA could compress any eventual commercial opportunity; management also acknowledges that if DMD, FA, and CPVT fail, platform value could fall to $0. As of September 30, 2025, it held about $236 million in cash, cash equivalents, investments, and available-for-sale securities, which may not be enough to fully fund development and commercialization without new partnerships or financings.